SCCA Purpose & Mission
Seattle Cancer Care Alliance (SCCA) unites the doctors from Fred Hutchinson Cancer Research Center, UW Medicine, and Seattle Children’s into one world-class treatment center. SCCA was incorporated in 1998 as a separate, jointly governed non-profit that includes the cancer programs of the three partners. Each partner has equal ownership of SCCA. Dr. Fred Appelbaum is the Executive Director of SCCA.
- Provide state-of-the-art, patient and family centered care.
- Support the conduct of cancer clinical research and education.
- Enhance access to improved cancer interventions, and advance the standard of cancer care regionally and beyond.
Lead the world in translating scientific discovery into the prevention, diagnosis, treatment, and cure of cancer.
In 2011 over 300 oncologists, surgeons, radiologists, pathologists, and research physicians treated over 5,500 patients for many types of cancers including leukemia, lymphoma, breast, prostate, lung, and colon cancer. SCCA patients have access to the latest cancer treatments including stem cell and bone marrow transplantation, gene therapy, specialized antibody therapies, high-dose chemotherapy, radiation therapy, immunotherapy, minimally invasive surgical techniques, and other specialized therapies. Patients receive their outpatient care at the SCCA clinic on Lake Union. Inpatient care is provided at UW Medical Center and Seattle Children’s.
Last year the Fred Hutchinson Bone Marrow Transplant Program at SCCA performed over 500 bone marrow transplants. In 2008, the program was ranked first in outcomes in a five-year study by the National Bone Marrow Donor Program that measured one-year survival rates of patients among 122 transplant centers in the United States.
A major focus of SCCA is to speed up the transfer of new diagnostic and treatment techniques from the research setting to patient care. The highly integrated approach to cancer research and treatment among SCCA partner organizations supports the flow of scientific information among researchers, clinicians, and patients, thereby accelerating the development of new knowledge and treatment of various cancers and blood disorders.